Barinthus Biotherapeutics plc (FRA:2AB)

Germany · Delayed Price · Currency is EUR

0.5850

+0.0200 (3.54%)

Last updated: Jun 10, 2026, 8:02 AM CET

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Research and Development of Immunotherapies and Vaccines		14.97M	802.00K	44.70M	268.00K	4.82M
Research and Development of Immunotherapies and Vaccines Growth		1766.46%	-98.21%	16580.22%	-94.44%	-29.57%
Total		14.97M	802.00K	44.70M	268.00K	4.82M
Total Growth		1766.46%	-98.21%	16580.22%	-94.44%	-29.57%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
United Kingdom		14.97M	802.00K	44.70M	268.00K	4.82M
United Kingdom Growth		1766.46%	-98.21%	16580.22%	-94.44%	-29.57%
Total		14.97M	802.00K	44.70M	268.00K	4.82M
Total Growth		1766.46%	-98.21%	16580.22%	-94.44%	-29.57%

Source: S&P Global Market Intelligence.